50 results about "Fusogenic peptide" patented technology

The invention relates to the technical field of antibacterial peptides, and discloses a preparation method and application of a multi-segment fused antibacterial peptide fusion protein. The antibacterial peptide fusion protein is obtained by introducing OST signal peptide and collagen and optimizing the connection sequence of the OST signal peptide, the collagen, bovine lactoferrin peptide LFcinB, bovine lactoferrin N-leaf small peptide LFcin and bovine lactoferrin N-leaf derived peptide Lf. The antibacterial peptide fusion protein can simultaneously contain three segments of bovine lactoferrin active peptides, namely LFcinB, LFcin and Lf, and the yield of the fusion peptide is maximized. Experiments prove that the fermentation yield of the fusion protein comprising the OST signal peptide, the collagen, the bovine lactoferrin peptide LFcinB, the bovine lactoferrin N-leaf small peptide LFcin and the bovine lactoferrin N-leaf derived peptide Lf which are sequentially connected from the N terminal to the C terminal can reach 600mg / L.

Fusion polypeptides are provided and comprise at least two ligand binding domains and a fragment crystallizable (Fc) region of immunoglobulin G (IgG). The ligand binding domains include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-25 and / or one of the at least two ligand binding domains binds modulates B cell activity while the other modulates T cell activity. Isolated nucleic acids, vectors, and isolated cells encoding or including the fusion peptides are further provided. Pharmaceutical compositions include the fusion peptides and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating Sjögren's Syndrome and / or Systemic Lupus Erythematosus are also provided and comprise administering to a subject in need thereof the fusion polypeptide including the two ligand binding domains and the Fc region of IgG.

The invention relates to the field of biological medicine preparation, and particularly provides liraglutide precursor peptide tandem recombinant fusion protein, polynucleotide, recombinant expression plasmid, engineered host cell and a method for preparing target polypeptide. The recombinant fusion protein is fusion peptide-target polypeptide-(linker peptide-target polypeptide) n from the N terminal to the C terminal, n is a positive integer from 4 to 6, the fusion peptide is SEQ ID NO.1, the target polypeptide is liraglutide precursor peptide, the linker peptide comprises a spacer peptide and a protease restriction enzyme cutting site, the spacer peptide is SEQ ID NO.2, the isoelectric point of the recombinant fusion protein is 4.6-4.7, and the average hydrophilic value is-0.780--0.765. The proportion of the target polypeptide in the recombinant fusion protein is high, use of solvents under extreme conditions is avoided in the production process, the enzyme digestion efficiency is high, and the product purity and yield are high.

The invention relates to the field of biological medicine preparation, and particularly provides canagliflozin precursor peptide tandem recombinant fusion protein, polynucleotide, recombinant expression plasmid, engineered host cell and a method for preparing target polypeptide. The recombinant fusion protein is a fusion peptide-target polypeptide-(linker peptide-target polypeptide) n from an N terminal to a C terminal, n is a positive integer of 4-6, the fusion peptide is SEQ ID NO.1 or SEQ ID NO.2, the target polypeptide is a canagliptin precursor peptide, the linker peptide comprises a spacer peptide and a protease restriction enzyme cutting site, the spacer peptide is SEQ ID NO.3, the isoelectric point of the recombinant fusion protein is 5.5-6.5, and the average hydrophilic value is-0.85--0.96. The invention creatively provides a method for preparing the canagliflozin precursor peptide by using a gene recombination technology, the proportion of the target polypeptide in the recombinant fusion protein is high, the use of a solvent under extreme conditions is avoided in the production process, the enzyme digestion efficiency is high, and the product purity and yield are high.

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.

The invention relates to construction of a fusion antibacterial peptide expression vector as well as an expression purification method and a purification device thereof, and belongs to the technical field of bioengineering. The preparation method comprises the following steps: fusing an antibacterial peptide to a C terminal of RNase denaturation form Onconase (ONC) protein from Rana pipiens, constructing an expression plasmid, and transforming the expression plasmid into escherichia coli to obtain gt; the yield of the inclusion body form fusion peptide is 300 mg / L. Gt is realized through operations of inclusion body washing, redissolving, acid hydrolysis, neutralization and the like; and the low-cost large-scale production of the 95% high-purity antibacterial peptide is realized. As a carrier protein, ONC has the advantages of high expression quantity, low toxicity, small molecular weight, specific pH solubility and the like. In the purification process, the inclusion body is dissolved by using a urea solution, and the purity and the yield of the antibacterial peptide are further improved by combining cation exchange chromatography and an ultrafiltration technology. According to the method and the device, the purification efficiency is remarkably improved, the labor investment is reduced, and the method and the device are suitable for wide industrial application.

The invention relates to the field of biological medicines, and discloses a fused adeno-associated virus and application thereof in ear diseases and ophthalmic diseases. The fusion adeno-associated virus comprises a fusion peptide fragment formed by fusing peptide fragments of serotype AAV1, 2, 6 and 7 or a variant of the fusion peptide fragment, can efficiently transduce hair cells and / or supporting cells in a cochlea, promote regeneration of internal hair cells and help to recover hearing, can also efficiently infect an RPE layer, and is used for treating ophthalmic diseases. As a safe vector, the fused adeno-associated virus has a wide application prospect in treatment of ear diseases or ophthalmic diseases.

The present invention relates to a novel peptide that specifically binds to nucleolin, and more specifically, to a peptide expressed by a specific amino acid sequence, a conjugate comprising the peptide and an anticancer drug, a fusion peptide comprising the peptide and a cell-penetrating peptide, a composition comprising the peptide for diagnosing cancer, and a composition comprising the peptide or the conjugate for preventing or treating cancer. In the present invention, the peptide ligand AGM peptide and its mutants, screened using the MAP synthesis method and the OBOC combination method, have been shown to specifically bind to cancer cells, and their conjugates with anticancer drugs inhibit cancer growth (in vitro and in vivo). Therefore, the AGM peptide targeting nucleolin can be effectively used for diagnosis and targeted drug delivery in cancer treatment.

The present disclosure relates to a chimeric receptor targeting mesothelin and its uses. The chimeric antigen receptor comprises a first fusion peptide and a second fusion peptide, wherein: the first fusion peptide comprises a mesothelin antigen-binding domain and a transmembrane domain; the second fusion peptide comprises a transmembrane domain, a cytoplasmic domain and a co-stimulatory domain. The chimeric antigen receptor of the present disclosure has good killing activity against mesothelin-expressing positive solid tumor cells.

The invention relates to a polypeptide, a preparation method and application thereof, and a drug for treating head and neck cancer, the polypeptide is an iRGD-TRP-PK1 fusion peptide, and comprises an iRGD targeting peptide sequence and a TRP-PK1 sequence; the iRGD-TRP-PK1 fusion peptide can specifically target an alpha v beta 3 integrin highly expressed on the surface of a tumor cell, and induces death of the tumor cell through a potassium leakage channel formed by TRP-PK1. The polypeptide provided by the invention can be combined with head and neck cancer cells with high expression of integrin alphaVbeta3, so that the operation complexity of a targeted delivery system is effectively reduced, the stability is improved, and a new treatment strategy and application prospect are provided for tumor treatment.

The invention relates to the technical field of biological medicines, and discloses a dual-targeting adhesion-immune activation fusion peptide, an anti-escherichia coli O157: H7 monoclonal antibody GS2-D3, curcumin nanoparticles and a probiotic composition composed of the curcumin nanoparticles. The fusion peptide solves structural conflicts by inserting an alpha helix stable domain composed of four EAAAK repetitive units and a GPGP flexible buffer domain, a targeting domain YIGSR and an MUC2 binding domain PTPSFTT are introduced to improve the targeting efficiency, and the enzymolysis resistance is enhanced through site mutation; the monoclonal antibody GS2-D3 can be used for specifically recognizing escherichia coli O157: H7; the curcumin nanoparticles improve the stability and bioavailability of curcumin. The probiotic composition contains the components, has the effects of efficient colonization, bacteriostasis, inflammation resistance and intestinal flora regulation, can effectively treat intestinal inflammation, is low in cost and high in safety, and has good clinical transformation potential.

The present application relates to a method for targeting and modulating a hepatitis B virus gene, which method comprises administering a pharmaceutical composition for inhibiting the expression of a hepatitis B virus (HBV) gene in cells. The pharmaceutical composition contains: 1) an epigenetic-modifying drug component which contains a fusion peptide or a complex peptide, or a nucleotide encoding the fusion peptide or complex peptide, wherein the fusion peptide or complex peptide contains at least one DNA-binding domain, at least one epigenetic-modifying domain, and at least one transcription-regulatory domain, and 2) a small nucleic acid drug component capable of targeting HBV and intervening with the expression thereof.

The present invention relates to fusogenic peptide carrier molecules for delivery of therapeutic nucleic acid to cells and methods of use thereof for the treatment of a disease or disorder.

The present invention provides compounds, compositions and methods for prophylaxis and treatment of traumatic brain injury using a P13 peptide or P13 fusion peptide which can be administered prior to or after traumatic brain injury and which can ameliorate the biophysiological indicators of brain injury and improve neurological outcomes in subjects suffering from traumatic brain injury.

This invention relates to the field of biomedical technology, and more particularly to a *Lactobacillus paracasei* strain with significant hypoglycemic effects. This invention develops an engineered bacterium that continuously secretes a mutant GLP-1 protein, capable of expressing a fusion peptide containing a signal peptide, an enhancing peptide, and the mutant GLP-1 protein. It exhibits good passage stability and can exert a dual therapeutic effect on type 2 diabetes through continuous secretion of the mutant GLP-1 protein and regulation of the gut microbiota. The engineered bacterium of this invention can be used to prepare oral pharmaceutical formulations. Therefore, this invention provides a new technical means for developing non-invasive, cost-effective, and efficient drug delivery strategies targeting GLP-1, and has broad application prospects.

The present invention relates to new methods for the purification of Fc-peptide fusion protein (peptibodies) derived from inclusion bodies after prokaryotic expression. In particular, it relates to chromatographic methods of the fusion peptides after refolding and dimerization comprising affinity capture, intermediate and polishing chromatographies. These methods facilitate the decrease of product-related impurities, such as sulfide variants or charge variants of the Fc-peptide fusion proteins in the final product. In addition, the present invention relates to specific conditions and selected buffers avoiding aggregation, precipitation, and degradation of the Fc-peptide fusion proteins. Finally, the methods of the present invention result in a formulated pharmaceutical composition or a pre-stage pharmaceutical composition containing an Fc-peptide fusion protein of high purity.

The invention relates to a novel anti-tumor active peptide, a pharmaceutical composition and application of the novel anti-tumor active peptide in preparation of anti-tumor drugs. The amino acid sequence of the active peptide is RHSGSYLVTSV. The invention also discloses a fusion peptide which is formed by linking a cell-penetrating peptide to the N tail end of the active peptide. The invention also discloses a pharmaceutical composition comprising the active peptide and other anti-tumor active components. The invention also discloses application of the active peptide or the pharmaceutical composition in preparation of medicines for treating tumors. The active peptide disclosed by the invention can be used for remarkably inhibiting the growth of tumors in animal bodies and improving the treatment effect of an immune checkpoint inhibitor PD-1 antibody, so that the aim of tumor immunotherapy is fulfilled. Therefore, the polypeptide provided by the invention can be used as a candidate drug for tumor immunotherapy, and has good potential clinical application value.

The invention discloses a construction method of genetically engineered bacteria X33-H-CZS-4 for expressing fusion peptide H-CZS-4, which comprises the following steps: step 1, preparing a fragment with an HSAD2-D3 tag, step 2, preparing a fragment containing a complete CZS-4 coding sequence, assembling the fragment containing the complete CZS-4 coding sequence and the fragment in the step 1 in escherichia coli Top10 competent cells to construct an expression plasmid pPICZalphaA-HSAD2-D3-CZS-4, and step 3, constructing the expression plasmid pPICZalphaA-HSAD2-D3-CZS-4 by using the expression plasmid pPICZalphaA-HSAD2-D3-CZS-4. The method comprises the following steps: 1, carrying out enzyme digestion on the expression plasmid pPICZalphaA-HSAD2-D3-CZS-4, 2, carrying out amplification culture on the expression plasmid pPICZalphaA-HSAD2-D3-CZS-4 to prepare pichia pastoris competent cells, 3, carrying out amplification culture on pichia pastoris X33 to prepare pichia pastoris competent cells, and 4, carrying out enzyme digestion linearization on the obtained expression plasmid pPICZalphaA-HSAD2-D3-CZS-4, and carrying out transformation on the expression plasmid pPICZalphaA-HSAD2-D3-CZS-4 and the pichia pastoris competent cells to obtain the According to the present invention, the peptide H-CZS-4 with the HSAD2-D3 tag is integrated into the pichia pastoris X33, such that the genetically engineered bacterium X33-H-CZS-4 expressing the fusion peptide H-CZS-4 is successfully constructed;

The invention discloses a snow flea antifreeze protein based on a cell penetrating peptide and application thereof, and belongs to the crossing field of genetic engineering and cell preservation technologies. The fusion protein rTAT-GS-MU obtained by fusing TAT peptide at the N end of rSfAFP-MU through a (G4S) 3 linker and a non-covalent compound of SfAFP-MU and Pep-1 are constructed, the intracellular delivery efficiency of the SfAFP-MU can be remarkably improved, the mitochondrial function of cells can be remarkably improved, and nuclear DNA damage can be reduced (the content of gamma-H2AX is reduced by 140% at most). The invention provides an important basis for developing a high-efficiency and low-toxicity broad-spectrum cell cryopreservation protective agent.

The invention discloses a multi-copy expression construction method of an insecticidal fusion peptide U10-MYRTX-Mri1a-GNA with bacteriostatic activity in pichia pastoris, which comprises the following steps: 1, carrying out reverse PCR (Polymerase Chain Reaction) on a plasmid pGAPZalpha A, introducing a Hind III restriction enzyme cutting site to obtain a plasmid pGAPZalpha A-Hind III, 2, constructing a fragment containing a U10-MYRTX-Mri1a gene, and 3, carrying out multi-copy expression on the fragment containing the U10-MYRTX-Mri1a gene to obtain the insecticidal fusion peptide U10-MYRTX-Mri1a gene. The method comprises the following steps: 1, constructing a U10-MYRTX-Mri1a gene fragment, 2, constructing a U10-MYRTX-Mri1a gene fragment, 3, introducing a GGGSAAA linker and a snowflake agglutinin (GNA)-6 * His label to the C end of the U10-MYRTX-Mri1a gene fragment, 4, constructing a multi-copy expression vector pGAPZalpha A-HindIII-Mira1-GNA * 3, 5, preparing a pichia pastoris competent cell X33, and 6, carrying out electrochemical conversion to obtain a genetically engineered bacterium X33-pGAPZalpha A-HindIII-Mira1-GNA * 3. According to the invention, a linearized plasmid is transferred to pichia pastoris X33, so that a genetically engineered bacterium for expressing the fusion peptide U10-MYRTX-Mri1a-GNA is obtained.

The present application relates to the technical field of biological medicine, and discloses a double-targeting adhesion-immune activation fusion peptide, an anti-E.coli O157:H7 monoclonal antibody GS2-D3, curcumin nanoparticles and a probiotic composition composed of the same. The fusion peptide solves the structural conflict by inserting an alpha-helix stable domain composed of four EAAAK repeat units and a GPGP flexible buffer domain, introduces a targeting domain YIGSR and a MUC2 binding domain PTPSFTT to improve the targeting efficiency, and is subjected to site mutation to enhance the anti-enzymatic property. The monoclonal antibody GS2-D3 can specifically recognize E.coli O157:H7. The curcumin nanoparticles improve the stability and bioavailability of curcumin. The probiotic composition contains the above components, has the effects of efficient colonization, bacteriostasis, anti-inflammation and regulation of intestinal flora, can effectively treat intestinal inflammation, has low cost and high safety, and has good clinical transformation potential.

The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

Provided is a method whereby it is possible to quickly and inexpensively quantify human insulin secreted from human cells. Specifically disclosed is a method for quantifying the insulin secretion ability of human cells, which is characterized by culturing a recombinant cell in which a gene expressing a fusion C-peptide and an insulin gene in a human cultured cell strain genome are replaced, and measuring the amount of the secreted fusion C-peptide. The fusion C-peptide is a fusion C-peptide obtained by inserting a detectable tag peptide into a C-peptide chain in a human proinsulin molecule.

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

A fusion peptide comprising a coronavirus HR2-derived peptide fused to an ACE2-derived peptide or a lipopeptide comprising the fusion protein and cholesterol is a broad spectrum inhibitor of a coronavirus.

The problem to be solved by the present invention is to provide a targeted anti-inflammatory therapy that reduces the self-perpetuating metabolic inflammation due to local LDL cholesterol in atherosclerotic plaques without significant systemic immunosuppression.SOLUTION: The present invention provides a polypeptide dimer comprising two gp130 - Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably high risk ASCVD in human patients, more preferably very high risk ASCVD in human patients.SELECTED DRAWING: None

The invention discloses a cell penetrating fusion peptide K300-pe. The amino acid sequence of the cell penetrating fusion peptide K300-pe is YGRKKRRQRRR YYRTADKGWQNSI. Researches find that FOXK2 lactoacylation modification can enhance the drug resistance of hepatoma carcinoma cells and hepatoma carcinoma tissues to sorafenib, and the FOXK2 lactoacylation modification site is located at the 300th lysine residue (K300) of the FOXK2 lactoacylation modification site; according to the invention, FOXK2 is taken as a template, a peptide fragment where a K300 site in FOXK2 is located is intercepted and fused with a cell-penetrating peptide CPPtat, and the obtained cell-penetrating fusion peptide K300-Pe can inhibit lactoacylation modification of FOXK2 in a targeted manner and increase the sensitivity of drug-resistant hepatoma cells and hepatoma tissues to sorafenib treatment, can be used for preparing FOXK2 lactic acid modification polypeptide inhibitors and drugs for enhancing the sensitivity of hepatocellular carcinoma to sorafenib treatment, and has broad application prospects. The compound can also be combined with sorafenib to prepare a medicine for resisting hepatocellular carcinoma.

The invention discloses an MYH2-FIGN interaction blocking amino acid compound and application thereof, and relates to the field of polypeptide drugs and tumor prevention and treatment. The MYH2-FIGN interaction blocking amino acid compound is an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 3 or a polypeptide derivative of the amino acid sequence. The invention also discloses a pharmaceutical composition, which comprises the MYH2-FIGN interaction blocking amino acid compound and a pharmaceutically acceptable carrier. The polypeptide drug targeting the MYH2-FIGN interaction interface is designed for the first time, compared with traditional small molecules, the polypeptide drug has specificity on MYH2-FIGN interaction inhibition, by means of fusion of iRGD peptide, the problem of polypeptide cell penetration is solved, tumor targeting is given to the polypeptide drug, the bioavailability of the drug is improved, systematic toxicity is reduced, and the polypeptide drug has good application prospects. The polypeptide medicine can adopt various medicine dosage forms, and the preparation process is simple.

The purpose of the present invention is to provide a novel means that targets M1 microglia and is useful for the treatment of central nervous system diseases and the like. Provided is an M1 microglia-targeting fusion peptide in which an M1 microglia-targeting peptide and an apoptosis-inducing peptide are directly or indirectly linked to each other, wherein the M1 microglia-targeting peptide is a peptide mentioned in (1) or (2): (1) a peptide which has a structure such that at least one cysteine residue is directly linked to each of both ends of the amino acid sequence represented by HHSSSAR (SEQ ID NO: 1) or an amino acid sequence formed by linking a plurality of the sequences; and (2) a peptide which comprises an amino acid sequence having a structure such that one amino acid residue is or a plurality of amino acid residues are deleted, substituted or added in the amino acid sequence for the peptide (1) and which targets M1 microglia.

This invention discloses a highly efficient oligonucleotide drug delivery system based on a fusion peptide, its preparation method, and its applications. The system includes a fusion peptide and an oligonucleotide drug. The fusion peptide is formed by linking a targeting peptide with a sorting signal peptide of a lysosomal targeting receptor on the cell surface. The fusion peptide is linked to the oligonucleotide drug via a linker. The advantages of this invention include: targeted, efficient, and stable delivery of oligonucleotides into cells to achieve gene therapy effects; low immunogenicity; high safety; high delivery efficiency; and wide applicability.